Retrieval of the Clipped Axillary Lymph Node and Its Impact on Treatment Decisions
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
3.1. Clipped Lymph Node
3.2. Factors Associated with Patholgic Complete Response (pCR)
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Boughey, J.C.; McCall, L.M.; Ballman, K.V.; Mittendorf, E.A.; Ahrendt, G.M.; Wilke, L.G.; Taback, B.; Leitch, A.M.; Flippo-Morton, T.; Hunt, K.K. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: Findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann. Surg. 2014, 260, 608–616. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- van der Noordaa, M.E.M.; van Duijnhoven, F.H.; Straver, M.E.; Groen, E.J.; Stokkel, M.; Loo, C.E.; Elkhuizen, P.H.M.; Russell, N.S.; Peeters, M.T.F.D.V. Major reduction in axillary lymph node dissections after neoadjuvant systemic therapy for node-positive breast cancer by combining PET/CT and the MARI procedure. Ann. Surg. Oncol. 2018, 25, 1512–1520. [Google Scholar] [CrossRef] [PubMed]
- Dominici, L.S.; Gonzalez, V.M.N.; Buzdar, A.U.; Lucci, A.; Mittendorf, E.A.; Le-Petross, H.T.; Babiera, G.V.; Meric-Bernstam, F.; Hunt, K.K.; Kuerer, H.M. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 2010, 116, 2884–2889. [Google Scholar] [CrossRef] [PubMed]
- Naoum, G.E.; Roberts, S.; Brunelle, C.L.; Shui, A.M.; Salama, L.; Daniell, K.; Gillespie, T.; Bucci, L.; Smith, B.L.; Ho, A.Y.; et al. Quantifying the Impact of Axillary Surgery and Nodal Irradiation on Breast Cancer–Related Lymphedema and Local Tumor Control: Long-Term Results from a Prospective Screening Trial. J. Clin. Oncol. 2020, 38, 3430–3438. [Google Scholar] [CrossRef] [PubMed]
- Lucci, A.; McCall, L.M.; Beitsch, P.D.; Whitworth, P.W.; Reintgen, D.S.; Blumencranz, P.W.; Leitch, A.M.; Saha, S.; Hunt, K.K.; Giuliano, A.E. Surgical Complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Compared With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011. J. Clin. Oncol. 2007, 25, 3657–3663. [Google Scholar] [CrossRef]
- Boughey, J.C.; Suman, V.J.; Mittendorf, E.A.; Ahrendt, G.M.; Wilke, L.G.; Taback, B.; Leitch, A.M.; Kuerer, H.M.; Bowling, M.; Flippo-Morton, T.S.; et al. Alliance for Clinical Trials in Oncology. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013, 310, 1455–1461. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Kuehn, T.; Bauerfeind, I.; Fehm, T.; Fleige, B.; Hausschild, M.; Helms, G.; Lebeau, A.; Liedtke, C.; Minckwitz, G.V.; Nekljudova, V.; et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study. Lancet Oncol. 2013, 14, 609–618. [Google Scholar] [CrossRef]
- Boileau, J.-F.; Poirier, B.; Basik, M.; Holloway, C.M.; Gaboury, L.; Sideris, L.; Meterissian, S.; Arnaout, A.; Brackstone, M.; McCready, D.R.; et al. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study. J. Clin. Oncol. 2015, 33, 258–264. [Google Scholar] [CrossRef]
- Boughey, J.C.; Ballman, K.V.; Le-Petross, H.T.; McCall, L.M.; Mittendorf, E.A.; Ahrendt, G.M.; Wilke, L.G.; Taback, B.; Feliberti, E.C.; Hunt, K.K. Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting with Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results from ACOSOG Z1071 (Alliance). Ann. Surg. 2016, 263, 802–807. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Caudle, A.S.; Yang, W.T.; Krishnamurthy, S.; Mittendorf, E.A.; Black, D.M.; Gilcrease, M.Z.; Bedrosian, I.; Hobbs, B.P.; DeSnyder, S.M.; Hwang, R.F.; et al. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients with Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J. Clin. Oncol. 2016, 34, 1072–1078. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Diego, E.J.; McAuliffe, P.F.; Soran, A.; McGuire, K.P.; Johnson, R.R.; Bonaventura, M.; Ahrendt, G.M. Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes. Ann. Surg. Oncol. 2016, 23, 1549–1553. [Google Scholar] [CrossRef]
- Gallagher, K.K.D.; Iles, K.; Kuzmiak, C.D.; Louie, R.; McGuire, K.P.M.; Ollila, D.W.M. Prospective Evaluation of Radar-Localized Reflector–Directed Targeted Axillary Dissection in Node-Positive Breast Cancer Patients after Neoadjuvant Systemic Therapy. J. Am. Coll. Surg. 2022, 234, 538–545. [Google Scholar] [CrossRef] [PubMed]
- Mamtani, A.; Barrio, A.V.; King, T.A.; Van Zee, K.J.; Plitas, G.; Pilewskie, M.; El-Tamer, M.; Gemignani, M.L.; Heerdt, A.S.; Sclafani, L.M.; et al. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients with Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann. Surg. Oncol. 2016, 23, 3467–3474. [Google Scholar] [CrossRef] [PubMed]
- Ende, N.S.v.D.; Nguyen, A.H.; Jager, A.; Kok, M.; Debets, R.; van Deurzen, C.H.M. Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review. Int. J. Mol. Sci. 2023, 24, 2969. [Google Scholar] [CrossRef] [PubMed]
- Connor, C.S.; Kimler, B.F.; Mammen, J.M.; McGinness, M.K.; Wagner, J.L.; Alsop, S.M.; Ward, C.; Fabian, C.J.; Khan, Q.J.; Sharma, P. Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer. J. Surg. Oncol. 2015, 111, 198–202. [Google Scholar] [CrossRef] [PubMed]
- Park, S.; Park, J.M.; Cho, J.H.; Park, H.S.; Kim, S.I.; Park, B.-W. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with cytologically proven node-positive breast cancer at diagnosis. Ann. Surg. Oncol. 2013, 20, 2858–2865. [Google Scholar] [CrossRef] [PubMed]
- Peleteiro, B.; Pinto, C.A.; Osório, F.; Costa, S.; Magalhães, A.; Mora, H.; Amaral, J.; Gonçalves, D.; Fougo, J.L. Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients. Breast Cancer 2022, 29, 709–719. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Boughey, J.C.; Hoskin, T.L.; Goetz, M.P. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Ann. Surg. Oncol. 2022, 29, 5747–5756. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Cao, S.; Liu, X.; Cui, J.; Liu, X.; Zhong, J.; Yang, Z.; Sun, D.; Wei, W. Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients. Breast 2021, 59, 256–269. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Classe, J.-M.; Loaec, C.; Gimbergues, P.; Alran, S.; de Lara, C.T.; Dupre, P.F.; Rouzier, R.; Faure, C.; Paillocher, N.; Chauvet, M.P.; et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: The GANEA 2 study. Breast Cancer Res. Treat. 2019, 173, 343–352. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.-Q.; Vo, N.-P.; Yen, Y.-C.; Tam, K.-W. Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data. Ann. Surg. Oncol. 2022, 29, 3038–3049. [Google Scholar] [CrossRef] [PubMed]
- Masuda, N.; Lee, S.-J.; Ohtani, S.; Im, Y.-H.; Lee, E.-S.; Yokota, I.; Kuroi, K.; Im, S.-A.; Park, B.-W.; Kim, S.-B.; et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N. Engl. J. Med. 2017, 376, 2147–2159. [Google Scholar] [CrossRef] [PubMed]
- Von Minckwitz, G.; Huang, C.-S.; Mano, M.S.; Loibl, S.; Mamounas, E.P.; Untch, M.; Wolmark, N.; Rastogi, P.; Schneeweiss, A.; Redondo, A.; et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N. Engl. J. Med. 2019, 380, 617–628. [Google Scholar] [CrossRef] [PubMed]
- Galimberti, V.; Fontana, S.K.R.; Vicini, E.; Morigi, C.; Sargenti, M.; Corso, G.; Magnoni, F.; Intra, M.; Veronesi, P. This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. Breast 2023, 67, 21–25. [Google Scholar] [CrossRef] [PubMed]
- Barrio, A.V.; Montagna, G.; Mamtani, A.; Sevilimedu, V.; Edelweiss, M.; Capko, D.; Cody, H.S., III; El-Tamer, M.; Gemignani, M.L.; Heerdt, A.; et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy—A rare event. JAMA Oncol. 2021, 7, 1851–1855. [Google Scholar] [CrossRef]
- Montagna, G.; Mrdutt, M.M.; Sun, S.X.; Hlavin, C.; Diego, E.J.; Wong, S.M.; Barrio, A.V.; Bruele, A.B.v.D.; Cabioglu, N.; Sevilimedu, V.; et al. Omission of Axillary Dissection Following Nodal Downstaging with Neoadjuvant Chemotherapy. JAMA Oncol. 2024, 10, 793. [Google Scholar] [CrossRef] [PubMed]
- Guo, X.; Liu, Z.; Sun, C.; Zhang, L.; Wang, Y.; Li, Z.; Shi, J.; Wu, T.; Cui, H.; Zhang, J.; et al. Deep learning radiomics of ultrasonography: Identifying the risk of axillary non-sentinel lymph node involvement in primary breast cancer. EBioMedicine 2020, 60, 103018. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Zheng, X.; Yao, Z.; Huang, Y.; Yu, Y.; Wang, Y.; Liu, Y.; Mao, R.; Li, F.; Xiao, Y.; Wang, Y.; et al. Deep learning radiomics can predict axillary lymph node status in early-stage breast cancer. Nat. Commun. 2020, 11, 1236, Erratum in: Nat. Commun. 2021, 12, 4370. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Togawa, R.; Riedel, F.; Feisst, M.; Fastner, S.; Gomez, C.; Hennigs, A.; Nees, J.; Pfob, A.; Schäfgen, B.; Stieber, A.; et al. Shear-wave elastography as a supplementary tool for axillary staging in patients undergoing breast cancer diagnosis. Insights Imaging 2024, 15, 196. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Mamounas, E.P.; Bandos, H.; White, J.R.; Julian, T.B.; Khan, A.J.; Shaitelman, S.F.; Torres, M.A.; Vicini, F.; Ganz, P.A.; McCloskey, S.A.; et al. NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC). J. Clin. Oncol. 2018, 36, TPS601. [Google Scholar] [CrossRef]
- Alliance A011022: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy. ClinicalTrials.gov # NCT01901094. Available online: https://clinicaltrials.gov/study/NCT01901094 (accessed on 26 August 2024).
- Boersma, L.J.; Mjaaland, I.; van Duijnhoven, F. Regional radiotherapy after primary systemic treatment for cN plus breast cancer patients. Breast 2023, 68, 181–188. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Garcia-Tejedor, A.; Ortega-Exposito, C.; Salinas, S.; Luzardo-González, A.; Falo, C.; Martinez-Pérez, E.; Pérez-Montero, H.; Soler-Monsó, M.T.; Bajen, M.-T.; Benitez, A.; et al. Axillary lymph node dissection versus radiotherapy in breast cancer with positive sentinel nodes after neoadjuvant therapy (ADARNAT trial). Front. Oncol. 2023, 13, 1184021. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
Median (Range) | |
---|---|
Age at diagnosis | 53.5 (25–79) |
N (%) | |
Clinical T stage | |
T1 | 8 (9.9) |
T2 | 52 (64.2) |
T3 | 19 (23.5) |
Unknown | 2 (2.5) |
Histology | |
Ductal | 80 (98.8) |
Lobular | 1 (1.2) |
Tumor subtype | |
HR+/HER2+ | 16 (19.8) |
HR+/HER2− | 16 (19.8) |
HR−/HER2+ | 8 (9.9) |
TNBC | 16 (19.8) |
Other | 25 (30.9) |
Clinical node status | |
N1 | 76 (93.8) |
N2/N3 | 5 (6.2) |
Median (Range) | |
---|---|
Number Nodes Removed (CLN + SLN or ALND) | 5 (1–27) |
Number SLN | 4 (1–10) |
Number SLN positive | 1(0–8) |
Number Positive Nodes | 1 (0–11) |
N (%) | |
Rate of Localized Node (CLN = SLN) | |
Yes | 68 (84.0) |
No | 13 (16.0) |
CN+ to pN0 Conversion | |
Yes | 41 (50.6) |
No | 40 (49.4) |
Axillary Node Dissection | |
Yes | 20 (24.7) |
No | 61 (75.3) |
CN+ to pN0 Conversion | ||||
---|---|---|---|---|
Covariate | No | Yes | p-Value | |
N = 40 | N = 41 | |||
Clinical Tumor Size | T1 | 4 (50) | 4 (50) | 0.041 |
T2 | 31 (59.6) | 21 (40.4) | ||
T3 | 5 (26.3) | 14 (73.7) | ||
Chemotherapy Regimen | ACT | 30 (61.2) | 19 (38.8) | 0.027 |
TCHP | 7 (28) | 18 (72) | ||
Other | 3 (42.9) | 4 (57.1) | ||
pCR Breast | No | 35 (74.5) | 12 (25.5) | <0.001 |
Yes | 5 (14.7) | 29 (85.3) | ||
pCR SLN | No | 34 (97.1) | 1 (2.9) | <0.001 |
Yes | 3 (9.7) | 28 (90.3) | ||
Unknown | 3 (20) | 12 (80) | ||
Tumor Subtype | HR+/HER2+ | 4 (25.0) | 12 (75.0) | 0.006 |
HR+/HER2− | 13 (81.3) | 3 (18.8) | ||
HR−/HER2+ | 2 (25.0) | 6 (75.0) | ||
TNBC | 6 (37.5) | 10 (62.5) | ||
Other | 15 (60.0) | 10 (40.0) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Detz Jr., D.; Hanssen, D.; Whiting, J.; Sun, W.; Czerniecki, B.; Hoover, S.; Khakpour, N.; Kiluk, J.; Laronga, C.; Mallory, M.; et al. Retrieval of the Clipped Axillary Lymph Node and Its Impact on Treatment Decisions. Cancers 2024, 16, 3001. https://doi.org/10.3390/cancers16173001
Detz Jr. D, Hanssen D, Whiting J, Sun W, Czerniecki B, Hoover S, Khakpour N, Kiluk J, Laronga C, Mallory M, et al. Retrieval of the Clipped Axillary Lymph Node and Its Impact on Treatment Decisions. Cancers. 2024; 16(17):3001. https://doi.org/10.3390/cancers16173001
Chicago/Turabian StyleDetz Jr., David, Diego Hanssen, Junmin Whiting, Weihong Sun, Brian Czerniecki, Susan Hoover, Nazanin Khakpour, John Kiluk, Christine Laronga, Melissa Mallory, and et al. 2024. "Retrieval of the Clipped Axillary Lymph Node and Its Impact on Treatment Decisions" Cancers 16, no. 17: 3001. https://doi.org/10.3390/cancers16173001